Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (591)	10/16/2001 10:53:51 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1833

Nice. A reminder that Biacore has no rights to plug-flow cytometry.......... Tuesday October 16, 9:01 pm Eastern Time Press Release SOURCE: Axiom Biotechnologies Inc. Axiom Awarded Two Patents Covering Use of Flow Cytometry in Drug Discovery SAN DIEGO--(BW HealthWire)--Oct. 16, 2001--Axiom Biotechnologies today announced that it had been issued two U. S. patents 6,242,209 and 6,280,967 for methods relating to the application of compounds to a flowing cell suspension and measuring of the real-time responses of individual cells flowing through a detector. These patents extend Axiom's flow-based drug discovery patent portofolio to flow cytometry. ``Real-time flow cytometry analysis of compound gradients on flowing cells has many significant advantages over conventional plate-based drug screening and profiling methods,'' said Pandi Veerapandian, President and CEO. The issued patents, both titled ``Cell Flow Apparatus and Methods for Real-Time Measurements of Cellular Responses'' solidify Axiom's dominant position in the area of flow-based drug discovery, and secure one of the main components of Axiom's physiogenomics gene-to-lead platform.`` Axiom's application of flow cytometry to drug discovery improves reproducibility, sensitivity, throughput and physiological relevance of assays, allowing researchers to choose better lead drug molecules for clinical development. In addition, flow cytometry makes it possible to use stem cells in drug discovery -- an important improvement over current pharmaceutical screening methods that employ mostly cancer cell lines. Axiom Biotechnologies is a privately-held company focused on the rapid discovery of more effective and safer therapeutics through the innovative use of human cells. Axiom developed a unique physiogenomics platform for discovering drugs that have better properties in humans, and that are more likely to succeed in clinical trials. The physiogenomics platform is based on human cell-based technologies for target validation and drug screening and profiling. The Company has internal discovery programs in gastroesophageal reflux disease, obesity and oncology, and is currently involved in several drug discovery collaborations built around specific classes of disease targets. Contact: Axiom Biotechnologies Inc., San Diego Michael Kozlowski, Ph.D., Chief Operating Officer 858/455-4500 Fax: 858/455-4501 mikek@axiombio.com axiombio.com